"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 7 | 8 |
| 2007 | 2 | 3 | 5 |
| 2008 | 3 | 2 | 5 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 6 | 7 |
| 2012 | 3 | 4 | 7 |
| 2013 | 4 | 7 | 11 |
| 2014 | 1 | 6 | 7 |
| 2015 | 3 | 6 | 9 |
| 2016 | 1 | 10 | 11 |
| 2017 | 5 | 7 | 12 |
| 2018 | 4 | 8 | 12 |
| 2019 | 8 | 9 | 17 |
| 2020 | 3 | 11 | 14 |
| 2021 | 5 | 11 | 16 |
| 2022 | 3 | 10 | 13 |
| 2023 | 3 | 16 | 19 |
| 2024 | 10 | 5 | 15 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Risk Factors for Regrowth After Nonoperative Management for Rectal Cancer. Ann Surg Oncol. 2025 May; 32(5):3098-3105.
-
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2025 Feb 01; 160(2):172-180.
-
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025 Jan; 31(1):144-151.
-
The Landmark Series: Neoadjuvant Radiotherapy in Extremity Soft Tissue Sarcoma-The Way to Hypofractionation. Ann Surg Oncol. 2025 Mar; 32(3):1489-1496.
-
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiol Artif Intell. 2025 Jan; 7(1):e240124.
-
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 Dec; 8:e2400288.
-
Risk of Surgical Overtreatment in cN1 Breast Cancer Patients who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD. Ann Surg Oncol. 2025 Mar; 32(3):2023-2028.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. Pract Radiat Oncol. 2025 Mar-Apr; 15(2):124-143.
-
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat. 2025 Feb; 210(1):191-203.